Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 5, Pages 1274
Publisher
MDPI AG
Online
2020-05-18
DOI
10.3390/cancers12051274
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Incidence of microsatellite instability‐high hepatocellular carcinoma among Japanese patients and response to pembrolizumab
- (2020) Tomokazu Kawaoka et al. HEPATOLOGY RESEARCH
- Molecular therapies for HCC: Looking outside the box
- (2020) Sandrine Faivre et al. JOURNAL OF HEPATOLOGY
- Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
- (2020) Ann-Lii Cheng et al. JOURNAL OF HEPATOLOGY
- Advances in molecular classification and precision oncology in hepatocellular carcinoma
- (2020) Sandra Rebouissou et al. JOURNAL OF HEPATOLOGY
- The polymorphism rs975484 in the protein arginine methyltransferase 1 gene modulates expression of immune checkpoint genes in hepatocellular carcinoma
- (2020) Michael Schonfeld et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1
- (2020) Naoshi Nishida et al. Liver Cancer
- Clinical implications of the dual blockade of the PD-1/PD-L1 and vascular endothelial growth factor axes in the treatment of hepatocellular carcinoma
- (2020) Naoshi Nishida Hepatobiliary Surgery and Nutrition
- Epigenetic modulation enhances immunotherapy for hepatocellular carcinoma
- (2019) Young K. Hong et al. CELLULAR IMMUNOLOGY
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells
- (2019) Hongyu Zhou et al. ONCOGENE
- Immunogenomic landscape of hepatocellular carcinoma with immune cell stroma and EBV-positive tumor-infiltrating lymphocytes
- (2019) Hyo Jeong Kang et al. JOURNAL OF HEPATOLOGY
- Genetic alterations and expression of PTEN and its relationship with cancer stem cell markers to investigate pathogenesis and to evaluate prognosis in hepatocellular carcinoma
- (2019) Dingbao Chen et al. JOURNAL OF CLINICAL PATHOLOGY
- Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
- (2019) Ming Yi et al. Molecular Cancer
- Hepatocellular Carcinoma
- (2019) Augusto Villanueva NEW ENGLAND JOURNAL OF MEDICINE
- Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma
- (2019) Lynn G. Feun et al. CANCER
- β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
- (2019) Marina Ruiz de Galarreta et al. Cancer Discovery
- New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma
- (2019) Mossenta et al. Cancers
- Dual PD ‐1 and VEGFR ‐2 blockade promotes vascular normalization and enhances anti‐tumor immune responses in HCC
- (2019) Kohei Shigeta et al. HEPATOLOGY
- The Immunobiology of Hepatocellular Carcinoma in Humans and Mice: Basic Concepts and Therapeutic Implications
- (2019) Jiajie Hou et al. JOURNAL OF HEPATOLOGY
- LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
- (2019) T Yau et al. ANNALS OF ONCOLOGY
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma
- (2019) Liang-qing Dong et al. JOURNAL OF HEPATOLOGY
- Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma
- (2018) Zachary J. Brown et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification
- (2018) Yutaka Kurebayashi et al. HEPATOLOGY
- Immune checkpoint blockade for the treatment of human hepatocellular carcinoma
- (2018) Naoshi Nishida et al. HEPATOLOGY RESEARCH
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- High number of PD-1 positive intratumoural lymphocytes predicts survival benefit of cytokine-induced killer cells for hepatocellular carcinoma patients
- (2018) Boyang Chang et al. LIVER INTERNATIONAL
- Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies
- (2018) James J Harding et al. CLINICAL CANCER RESEARCH
- Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of Hepatocellular Carcinoma
- (2018) Hyung-Don Kim et al. GASTROENTEROLOGY
- Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade
- (2018) Jeffrey J. Ishizuka et al. NATURE
- Systemic Therapy for Hepatocellular Carcinoma: Latest Advances
- (2018) Masatoshi Kudo Cancers
- Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives
- (2017) Gaël S. Roth et al. EUROPEAN JOURNAL OF CANCER
- Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas
- (2017) Guoying Zhou et al. GASTROENTEROLOGY
- Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
- (2017) Daniela Sia et al. GASTROENTEROLOGY
- Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection
- (2017) Romain Désert et al. HEPATOLOGY
- Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1
- (2017) Hui Li et al. HEPATOLOGY
- Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification
- (2017) Julien Calderaro et al. JOURNAL OF HEPATOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Oncogenic Signal and Tumor Microenvironment in Hepatocellular Carcinoma
- (2017) Naoshi Nishida et al. ONCOLOGY
- Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features
- (2016) Julien Calderaro et al. HEPATOLOGY
- Immunological Microenvironment of Hepatocellular Carcinoma and Its Clinical Implication
- (2016) Naoshi Nishida et al. ONCOLOGY
- Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC
- (2016) A. Gabrielson et al. Cancer Immunology Research
- MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma
- (2016) Naoshi Nishida et al. Liver Cancer
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma
- (2015) Naoshi Nishida et al. DIGESTIVE DISEASES
- Genetic Landscape and Biomarkers of Hepatocellular Carcinoma
- (2015) Jessica Zucman-Rossi et al. GASTROENTEROLOGY
- Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages
- (2015) Wenjiang Yan et al. GUT
- Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets
- (2015) Kornelius Schulze et al. NATURE GENETICS
- Immunological landscape and immunotherapy of hepatocellular carcinoma
- (2015) Jesús Prieto et al. Nature Reviews Gastroenterology & Hepatology
- Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy
- (2014) Yuichiroh Umemoto et al. JOURNAL OF GASTROENTEROLOGY
- Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF- 1
- (2014) H. Li et al. JOURNAL OF IMMUNOLOGY
- Exploration of liver cancer genomes
- (2014) Tatsuhiro Shibata et al. Nature Reviews Gastroenterology & Hepatology
- Increase in CD14+HLA-DR−/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis
- (2013) Fumitaka Arihara et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma
- (2013) Tim Hon Man Chan et al. GUT
- Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice
- (2013) Yunching Chen et al. HEPATOLOGY
- Recent Advancements in Comprehensive Genetic Analyses for Human Hepatocellular Carcinoma
- (2013) Naoshi Nishida et al. ONCOLOGY
- Unique Association between Global DNA Hypomethylation and Chromosomal Alterations in Human Hepatocellular Carcinoma
- (2013) Naoshi Nishida et al. PLoS One
- High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions
- (2013) Jean Charles Nault et al. Nature Communications
- Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma
- (2012) Naoshi Nishida et al. HEPATOLOGY
- Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators
- (2012) Akihiro Fujimoto et al. NATURE GENETICS
- Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma
- (2012) Cécile Guichard et al. NATURE GENETICS
- Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO
- (2011) Tuanjie Li et al. CANCER LETTERS
- Genetic and Epigenetic Signatures in Human Hepatocellular Carcinoma:A Systematic Review
- (2011) Naoshi Nishida et al. CURRENT GENOMICS
- Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
- (2011) Sergio A. Quezada et al. IMMUNOLOGICAL REVIEWS
- Selective Recruitment of Regulatory T Cell through CCR6-CCL20 in Hepatocellular Carcinoma Fosters Tumor Progression and Predicts Poor Prognosis
- (2011) Kang-Jie Chen et al. PLoS One
- Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements
- (2010) Yujin Hoshida et al. SEMINARS IN LIVER DISEASE
- Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
- (2009) Q. Gao et al. CLINICAL CANCER RESEARCH
- A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells
- (2008) Bastian Hoechst et al. GASTROENTEROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now